$EVOK Hopefully you were paying attention when I posted this recently. Most weren’t, I’m sure. And that’s too bad because $2 was a good price for these shares.
$EVOK is a small cap company that’s still losing money but they may finally be moving in the right direction. Resistance and support are not exactly a straight line but more like an area that needs to be breached before we can consider this a solid move higher (see the chart below with the yellow area identified). This week the shares moved decisively above $2 on expanding volume while at the same time momentum has turned higher. This is on my watchlist for potential accumulation. Description: Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which has completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
View original message
  • 3
  • 1
3 Likes